LAMBDA 002 (Lung Registry) Study
← catalyst calendarNCT05170425 · readout ≤ 12 d
Sponsored by Natera, Inc. (industry) · NTRA — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
154actual
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-04 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lung Transplant Rejection
Intervention
- Device: Prospera
Primary outcome
what the primary-completion date above is the date OFPercent of donor-derived cell-free DNA (ddcfDNA) measured via the Prospera test
measured 3 years
Permalink · NTRA's whole pipeline · Catalyst calendar · Every registered study · What changed